Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Taimei Medical Technology Co (FRA:A2V) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Zhejiang Taimei Medical Technology Co ROA % Related Terms
Zhejiang Taimei Medical Technology Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Taimei Medical Technology Co ROA % Chart
Zhejiang Taimei Medical Technology Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
ROA %
-26.57
-22.46
-20.59
-14.32
-2.62
Zhejiang Taimei Medical Technology Co Semi-Annual Data
For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Taimei Medical Technology Co ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's ROA % distribution charts can be found below:
* The bar in red indicates where Zhejiang Taimei Medical Technology Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a ROA % of -2.61% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. According to the industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #473 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 69.7%.
Is Zhejiang Taimei Medical Technology Co's ROA % too high?
Zhejiang Taimei Medical Technology Co's current ROA % is -2.61%. Based on the distribution chart, Zhejiang Taimei Medical Technology Co ranks #473 out of 679 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Zhejiang Taimei Medical Technology Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Taimei Medical Technology Co's ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Zhejiang Taimei Medical Technology Co ranks #473 out of 679 companies for ROA %. This places Zhejiang Taimei Medical Technology Co in the lower half of its industry. The industry median ROA % is 1.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.85, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zhejiang Taimei Medical Technology Co and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Taimei Medical Technology Co's current ROA % is -2.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Taimei Medical Technology Co stock overvalued right now?
Zhejiang Taimei Medical Technology Co (FRA:A2V) has a current ROA % of -2.61%. The current ROA % is -2.61%. Zhejiang Taimei Medical Technology Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Zhejiang Taimei Medical Technology Co (FRA:A2V), the current ROA % is -2.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China. It designs and delivers industry-specific software and digital services that facilitate research and development (R&D) and the commercialization of pharmaceuticals and medical devices. The software it offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. It has a geographical presence in Mainland China, the United States, Singapore, Korea, and Others.
11GF Score
Get the complete analysis for FRA:A2V
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2V has been successfully added to your 
